These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1132 related articles for article (PubMed ID: 12063971)

  • 1. Metastasectomy and active specific immunotherapy for a large single melanoma metastasis.
    Baars A; van Riel JM; Cuesta MA; Jaspars EH; Pinedo HM; van den Eertwegh AJ
    Hepatogastroenterology; 2002; 49(45):691-3. PubMed ID: 12063971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
    Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM
    Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active immunotherapy with allogeneic tumor cell vaccines: present status.
    Chan AD; Morton DL
    Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis.
    Spitler LE; Wong P; Sagebiel R
    Arch Dermatol; 1978 Oct; 114(10):1501-4. PubMed ID: 718187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
    Sosman JA; Sondak VK
    Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
    Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
    Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.
    Tagawa ST; Cheung E; Banta W; Gee C; Weber JS
    Cancer; 2006 Mar; 106(6):1353-7. PubMed ID: 16475151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
    Sondak VK; Sosman JA
    Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
    van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
    Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant immunotherapy for vulvar malignant melanoma.
    Wallach RC; Taub RN
    Mt Sinai J Med; 1979; 46(2):161-2. PubMed ID: 312443
    [No Abstract]   [Full Text] [Related]  

  • 14. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
    Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
    Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination of surgery and immunotherapy in the treatment of melanoma. Experience of the National Institute of Oncology].
    Beltrán-Ortega A; Ramírez-Ugalde MT; Mora-Tiscareño A
    Gac Med Mex; 1978 Jan; 114(1):29-36. PubMed ID: 669131
    [No Abstract]   [Full Text] [Related]  

  • 18. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine therapy for melanoma: current status and future directions.
    Terando AM; Faries MB; Morton DL
    Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy as part of combinations for the treatment of cancer.
    Mitchell MS
    Int Immunopharmacol; 2003 Aug; 3(8):1051-9. PubMed ID: 12860162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.